While generally effective, clinical trials and real-world analyses demonstrate that a substantial proportion of patients do not show adequate response to this drug class, with retinal edema persisting in upwards of 60% of cases after one to two years of therapy, exhibiting suboptimal visual outcomes and insufficient disease control, with VEGF independent pathways remaining unaddressed. Here, VEGFA is linked to retinal edema.